🇺🇸 FDA
Pipeline program

ICS+LABA

20110505

Approved small_molecule completed

Quick answer

ICS+LABA for Bronchiectasis is a Approved program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
Bronchiectasis
Phase
Approved
Modality
small_molecule
Status
completed

Clinical trials